Two Phase 3 Trials of Baricitinib for Alopecia Areata

Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-05, Vol.386 (18), p.1687-1699
Hauptverfasser:	King, Brett, Ohyama, Manabu, Kwon, Ohsang, Zlotogorski, Abraham, Ko, Justin, Mesinkovska, Natasha A, Hordinsky, Maria, Dutronc, Yves, Wu, Wen-Shuo, McCollam, Jill, Chiasserini, Chiara, Yu, Guanglei, Stanley, Sarah, Holzwarth, Katrin, DeLozier, Amy M, Sinclair, Rodney
Format:	Artikel
Sprache:	eng
Schlagworte:	Acne Adult Allergy Alopecia Alopecia Areata - drug therapy Autoimmune Disease Autoimmune diseases Azetidines - adverse effects Azetidines - therapeutic use Baldness Cholesterol Clinical Medicine Clinical Medicine General Clinical trials Creatine Creatine kinase Cytokines Dermatology Dermatology General FDA approval Hair Hair loss Hematology High density lipoprotein Humans Immunology Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - therapeutic use Laboratories Oncology Oncology General Pathogenesis Placebos Purines - adverse effects Purines - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Scalp Statistical analysis Sulfonamides - adverse effects Sulfonamides - therapeutic use T-Cells
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2110343